Vitreomacular interface diseases: Pathophysiology, diagnosis and future treatment options

Expert Review of Ophthalmology

Volumn 7, Issue 4, 2012, Pages 311-323

  Girach, Aniz ^a   Pakola, Steve ^b  

^a ThromboGenics NV   (Belgium)

^b Amakem   (United States)

Author keywords

intravitreal injection; macular hole; microplasmin; ocriplasmin; pharmacological vitreolysis; vitrectomy; vitreomacular adhesion; vitreomacular interface; vitreomacular traction

Indexed keywords

CLOSTRIDIOPEPTIDASE A; COLLAGENASE; DISPASE; HYALURONIDASE; N ACETYLGALACTOSAMINE 4 SULFATASE; NATTOKINASE; OCRIPLASMIN; PLACEBO; PLASMIN; PLASMINOGEN ACTIVATOR; SERINE PROTEINASE; UNCLASSIFIED DRUG;

CATARACT; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; FUNCTIONAL ANATOMY; HUMAN; IRITIS; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PREVALENCE; RETINA HEMORRHAGE; RETINA MACULA EDEMA; RETINA MACULA HOLE; RETINA MACULOPATHY; REVIEW; VITRECTOMY; VITREOMACULAR ADHESION; VITREOMACULAR TRACTION; VITREOUS BODY DETACHMENT; VITREOUS DISEASE; VITREOUS HEMORRHAGE;

EID: 84866922857     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/eop.12.34     Document Type: Review

References (112)

1. Johnson MW. Posterior vitreous detachment: Evolution and complications of its early stages. Am. J. Ophthalmol. 149(3), 371-382 (2010).
2. Krebs I, Brannath W, Glittenberg C, Zeiler F, Sebag J, Binder S. Posterior vitreomacular adhesion: A potential risk factor for exudative age-related macular degeneration? Am. J. Ophthalmol. 144(5), 741-746 (2007).
3. Hikichi T, Yoshida A, Trempe CL. Course of vitreomacular traction syndrome. Am. J. Ophthalmol. 119(1), 55-61 (1995).
4. Sonmez K, Capone A Jr, Trese MT, Williams GA. Vitreomacular traction syndrome: Impact of anatomical configuration on anatomical and visual outcomes. Retina (Philadelphia, PA) 28(9), 1207-1214 (2008).
5. Melberg NS, Williams DF, Balles MW et al. Vitrectomy for vitreomacular traction syndrome with macular detachment. Retina (Philadelphia, PA) 15(3), 192-197 (1995).
6. Sebag J. Molecular biology of pharmacologic vitreolysis. Trans. Am. Ophthalmol. Soc. 103, 473-494 (2005). (Pubitemid 43042095)
7. Guillaubey A, Malvitte L, Lafontaine PO et al. Incidence of retinal detachment after macular surgery: A retrospective study of 634 cases. Br. J. Ophthalmol. 91(10), 1327-1330 (2007). (Pubitemid 47492867)
8. Ramkissoon YD, Aslam SA, Shah SP, Wong SC, Sullivan PM. Risk of iatrogenic peripheral retinal breaks in 20-G pars plana vitrectomy. Ophthalmology 117(9), 1825-1830 (2010).
9. Rizzo S, Belting C, Genovesi-Ebert F, di Bartolo E. Incidence of retinal detachment after small-incision, sutureless pars plana vitrectomy compared with conventional 20-gauge vitrectomy in macular hole and epiretinal membrane surgery. Retina (Philadelphia, PA) 30(7), 1065-1071 (2010).
10. Recchia FM, Scott IU, Brown GC, Brown MM, Ho AC, Ip MS. Small-gauge pars plana vitrectomy: A report by the American Academy of Ophthalmology. Ophthalmology 117(9), 1851-1857 (2010).
11. Cheng L, Azen SP, El-Bradey MH et al. Duration of vitrectomy and postoperative cataract in the vitrectomy for macular hole study. Am. J. Ophthalmol. 132(6), 881-887 (2001). (Pubitemid 33122168)
12. Banker AS, Freeman WR, Kim JW, Munguia D, Azen SP. Vision-threatening complications of surgery for full-thickness macular holes. Vitrectomy for Macular Hole Study Group. Ophthalmology 104(9), 1442-1452; discussion 1452 (1997).
13. Freeman WR, Azen SP, Kim JW, el-Haig W, Mishell DR 3rd, Bailey I; The Vitrectomy for Treatment of Macular Hole Study Group. Vitrectomy for the treatment of full-thickness stage 3 or 4 macular holes. Results of a multicentered randomized clinical trial. Arch. Ophthalmol. 115(1), 11-21 (1997).
14. Sebag J. Pharmacologic vitreolysis. Retina 18(1), 1-3 (1998).
15. Bishop PN. Structural macromolecules and supramolecular organisation of the vitreous gel. Prog. Retin. Eye Res. 19(3), 323-344 (2000). (Pubitemid 30122726)
16. Reardon AJ, Le Goff M, Briggs MD et al. Identification in vitreous and molecular cloning of opticin, a novel member of the family of leucine-rich repeat proteins of the extracellular matrix. J. Biol. Chem. 275(3), 2123-2129 (2000). (Pubitemid 30060841)
17. Hindson VJ, Gallagher JT, Halfter W, Bishop PN. Opticin binds to heparan and chondroitin sulfate proteoglycans. Invest. Ophthalmol. Vis. Sci. 46(12), 4417-4423 (2005). (Pubitemid 44264533)
18. Scott JE, Chen Y, Brass A. Secondary and tertiary structures involving chondroitin and chondroitin sulphates in solution, investigated by rotary shadowing/electron microscopy and computer simulation. Eur. J. Biochem. 209(2), 675-680 (1992).
19. Le Goff MM, Bishop PN. Adult vitreous structure and postnatal changes. Eye 22(10), 1214-1222 (2008).
20. Wang J, McLeod D, Henson DB, Bishop PN. Age-dependent changes in the basal retinovitreous adhesion. Invest. Ophthalmol. Vis. Sci. 44(5), 1793-1800 (2003). (Pubitemid 36520263)
21. Matsumoto B, Blanks JC, Ryan SJ. Topographic variations in the rabbit and primate internal limiting membrane. Invest. Ophthalmol. Vis. Sci. 25(1), 71-82 (1984). (Pubitemid 14220990)
22. Bishop PN, Holmes DF, Kadler KE, McLeod D, Bos KJ. Age-related changes on the surface of vitreous collagen fibrils. Invest. Ophthalmol. Vis. Sci. 45(4), 1041-1046 (2004). (Pubitemid 38869005)
23. Larsson L, Osterlin S. Posterior vitreous detachment. A combined clinical and physiochemical study. Graefes Arch. Clin. Exp. Ophthalmol. 223(2), 92-95 (1985). (Pubitemid 15051685)
24. Vaughan-Thomas A, Gilbert SJ, Duance VC. Elevated levels of proteolytic enzymes in the aging human vitreous. Invest. Ophthalmol. Vis. Sci. 41(11), 3299-3304 (2000).
25. Russell SR, Shepherd JD, Hageman GS. Distribution of glycoconjugates in the human retinal internal limiting membrane. Invest. Ophthalmol. Vis. Sci. 32(7), 1986-1995 (1991).
26. Sebag J. Anomalous posterior vitreous detachment: A unifying concept in vitreo-retinal disease. Graefes Arch. Clin. Exp. Ophthalmol. 242(8), 690-698 (2004). (Pubitemid 39242846)
27. Smiddy WE, Green WR, Michels RG, de la Cruz Z. Ultrastructural studies of vitreomacular traction syndrome. Am. J. Ophthalmol. 107(2), 177-185 (1989). (Pubitemid 19049846)
28. Shinoda K, Hirakata A, Hida T et al Ultrastructural and immunohistochemical findings in five patients with vitreomacular traction syndrome. Retina 20(3), 289-293 (2000). (Pubitemid 30436782)
29. Wu PC, Chen YJ, Chen YH et al. Factors associated with foveoschisis and foveal detachment without macular hole in high myopia. Eye 23(2), 356-361 (2009).
30. Shechtman DL, Dunbar MT. The expanding spectrum of vitreomacular traction. Optometry 80(12), 681-687 (2009).
31. Ito Y, Terasaki H, Suzuki T et al. Mapping posterior vitreous detachment by optical coherence tomography in eyes with idiopathic macular hole. Am. J. Ophthalmol. 135(3), 351-355 (2003). (Pubitemid 36279522)
32. Huang D, Swanson EA, Lin CP et al. Optical coherence tomography. Science 254(5035), 1178-1181 (1991). (Pubitemid 21917444)
33. Chang LK, Fine HF, Spaide RF, Koizumi H, Grossniklaus HE. Ultrastructural correlation of spectral-domain optical coherence tomographic findings in vitreomacular traction syndrome. Am. J. Ophthalmol. 146(1), 121-127 (2008).
34. van Velthoven ME, Faber DJ, Verbraak FD, van Leeuwen TG, de Smet MD. Recent developments in optical coherence tomography for imaging the retina. Prog. Retin. Eye Res. 26(1), 57-77 (2007). (Pubitemid 44894994)
35. Do DV, Cho M, Nguyen QD et al. The impact of optical coherence tomography on surgical decision making in epiretinal membrane and vitreomacular traction. Trans. Am. Ophthalmol. Soc. 104, 161-166 (2006).
36. Gallemore RP, Jumper JM, McCuen BW 2nd, Jaffe GJ, Postel EA, Toth CA. Diagnosis of vitreoretinal adhesions in macular disease with optical coherence tomography. Retina 20(2), 115-120 (2000). (Pubitemid 30395704)
37. Sayegh RG, Georgopoulos M, Geitzenauer W, Simader C, Kiss C, Schmidt-Erfurth U. High-resolution optical coherence tomography after surgery for vitreomacular traction: A 2-year follow-up. Ophthalmology 117(10), 2010-2017 (2010).
38. Tammewar AM, Bartsch DU, Kozak I et al. Imaging vitreomacular interface abnormalities in the coronal plane by simultaneous combined scanning laser and optical coherence tomography. Br. J. Ophthalmol. 93(3), 366-372 (2009).
39. Chew EY, Sperduto RD, Hiller R et al. Clinical course of macular holes: The Eye Disease Case-Control Study. Arch. Ophthalmol. 117(2), 242-246 (1999). (Pubitemid 29091821)
40. Morgan CM, Schatz H. Idiopathic macular holes. Am. J. Ophthalmol. 99(4), 437-444 (1985). (Pubitemid 15034507)
41. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am. J. Ophthalmol. 146(6), 930-934 (2008).
42. Akiba J, Yoshida A, Trempe CL. Risk of developing a macular hole. Arch. Ophthalmol. 108(8), 1088-1090 (1990). (Pubitemid 20265265)
43. Ezra E. Idiopathic full thickness macular hole: Natural history and pathogenesis. Br. J. Ophthalmol. 85(1), 102-108 (2001). (Pubitemid 32060207)
44. Thompson JT, Sjaarda RN, Lansing MB. The results of vitreous surgery for chronic macular holes. Retina 17(6), 493-501 (1997). (Pubitemid 28032430)
45. Gaucher D, Haouchine B, Tadayoni R et al. Long-term follow-up of high myopic foveoschisis: Natural course and surgical outcome. Am. J. Ophthalmol. 143(3), 455-462 (2007).
46. Nasrallah FP, Jalkh AE, Van Coppenolle F et al. The role of the vitreous in diabetic macular edema. Ophthalmology 95(10), 1335-1339 (1988).
47. Avunduk AM, Cetinkaya K, Kapicioglu Z, Kaya C. The effect of posterior vitreous detachment on the prognosis of branch retinal vein occlusion. Acta Ophthalmol. Scand. 75(4), 441-442 (1997). (Pubitemid 27470477)
48. Haller JA, Qin H, Apte RS et al.; Diabetic Retinopathy Clinical Research Network Writing Committee. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 117(6), 1087-1093.e3 (2010).
49. Mojana F, Cheng L, Bartsch DU et al. The role of abnormal vitreomacular adhesion in age-related macular degeneration: Spectral optical coherence tomography and surgical results. Am. J. Ophthalmol. 146(2), 218-227 (2008).
50. Robison CD, Krebs I, Binder S et al. Vitreomacular adhesion in active and endstage age-related macular degeneration. Am. J. Ophthalmol. 148, 79-82 (2009).
51. Uchino E, Uemura A, Ohba N. Initial stages of posterior vitreous detachment in healthy eyes of older persons evaluated by optical coherence tomography. Arch. Ophthalmol. 119(10), 1475-1479 (2001). (Pubitemid 32963251)
52. Panozzo G, Mercanti A. Optical coherence tomography findings in myopic traction maculopathy. Arch. Ophthalmol. 122(10), 1455-1460 (2004). (Pubitemid 39336544)
53. The Eye Disease Case-Control Study Group. Risk factors for idiopathic macular holes: The Eye Disease Case-Control Study Group. Am. J. Ophthalmol. 118, 754-761 (1994).
54. McCannel CA, Ensminger JL, Diehl NN, Hodge DN. Population-based incidence of macular holes. Ophthalmology 116(7), 1366-1369 (2009).
55. Huang LL, Levinson DH, Levine JP, Mian U, Tsui I. Optical coherence tomography findings in idiopathic macular holes. J. Ophthalmol. 2011, 928205 (2011).
56. Krebs I, Brannath W, Glittenberg C et al. Posterior vitreomacular adhesion: A potential risk factor for exudative age-related macular degeneration? Am. J. Ophthalmol. 144, 741-746 (2007).
57. Lee SJ, Lee CS, Koh HJ. Posterior vitreomacular adhesion and risk of exudative age-related macular degeneration: Paired eye study. Am. J. Ophthalmol. 147(4), 621-626 (2009).
58. Robison CD, Krebs I, Binder S et al. Vitreomacular adhesion in active and end-stage age-related macular degeneration. Am. J. Ophthalmol. 148(1), 79-82 (2009).
59. Mojana F, Cheng L, Bartsch DU et al. The role of abnormal vitreomacular adhesion in age-related macular degeneration: Spectral optical coherence tomography and surgical results. Am. J. Ophthalmol. 146, 218-227 (2008).
60. Sebag J. Pharmacologic vitreolysis - premise and promise of the first decade. Retina 29(7), 871-874 (2009).
61. Hageman GS, Russell SR. Chondroitinasemediated disinsertion of the primate vitreous body. Invest. Ophthalmol. Vis. Sci. 35, 1260 (1994).
62. Staubach F, Nober V, Janknecht P. Enzyme-assisted vitrectomy in enucleated pig eyes: A comparison of hyaluronidase, chondroitinase, and plasmin. Curr. Eye Res. 29, 261-268 (2004). (Pubitemid 40095009)
63. Hermel M, Schrage NF. Efficacy of plasmin enzymes and chondroitinase ABC in creating posterior vitreous separation in the pig: A masked, placebo-controlled in vivo study. Graefes Arch. Clin. Exp. Ophthalmol. 245(3), 399-406 (2007). (Pubitemid 46404001)
64. O'Neill R, Shea M. The effects of bacterial collagenase in rabbit vitreous. Can. J. Ophthalmol. 8(2), 366-370 (1973).
65. Moorhead LC, Radtke N. Enzyme-assisted vitrectomy with bacterial collagenase. Pilot human studies. Retina 5(2), 98-100 (1985). (Pubitemid 15004316)
66. Takahashi K, Nakagawa M, Ninomiya H et al. Enzyme-assisted vitrectomy with collagenase. Jpn. J. Clin. Ophthalmol. 47, 802-803 (1993).
67. Stenn KS, Link R, Moellmann G, Madri J, Kuklinska E. Dispase, a neutral protease from Bacillus polymyxa, is a powerful fibronectinase and type IV collagenase. J. Invest. Dermatol. 93(2), 287-290 (1989). (Pubitemid 19202441)
68. Oliveira LB, Tatebayashi M, Mahmoud TH, Blackmon SM, Wong F, McCuen BW 2nd. Dispase facilitates posterior vitreous detachment during vitrectomy in young pigs. Retina 21(4), 324-331 (2001). (Pubitemid 32769245)
69. Tezel TH, Del Priore LV, Kaplan HJ. Posterior vitreous detachment with dispase. Retina 18(1), 7-15 (1998). (Pubitemid 28128399)
70. Jorge R, Oyamaguchi EK, Cardillo JA, Gobbi A, Laicine EM, Haddad A. Intravitreal injection of dispase causes retinal hemorrhages in rabbit and human eyes. Curr. Eye Res. 26(2), 107-112 (2003). (Pubitemid 36776117)
71. Zhu D, Chen H, Xu X. Effects of intravitreal dispase on vitreoretinal interface in rabbits. Curr. Eye Res. 31(11), 935-946 (2006).
72. Wang F, Wang Z, Sun X, Wang F, Xu X, Zhang X. Safety and efficacy of dispase and plasmin in pharmacologic vitreolysis. Invest. Ophthalmol. Vis. Sci. 45(9), 3286-3290 (2004). (Pubitemid 39121868)
73. Kaplan HJ, Tezel TH, Del Priore LV. Purification of the active constituents of dispase for vitreopharmacolysis. Invest. Ophthalmol. Vis. Sci. 46, E-abstract 5454 (2005).
74. Narayanan R, Kuppermann BD. Hyaluronidase for pharmacologic vitreolysis. Dev. Ophthalmol. 44, 20-25 (2009).
75. Gottlieb JL, Antoszyk AN, Hatchell DL, Saloupis P. The safety of intravitreal hyaluronidase. A clinical and histologic study. Invest. Ophthalmol. Vis. Sci. 31(11), 2345-2352 (1990).
76. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR; Vitrase for Vitreous Hemorrhage Study Groups. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am. J. Ophthalmol. 140(4), 573-584 (2005). (Pubitemid 41455296)
77. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR; Vitrase for Vitreous Hemorrhage Study Groups. Safety results of two Phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am. J. Ophthalmol. 140(4), 585-597 (2005).
78. Wang ZL, Zhang X, Xu X, Sun XD, Wang F. PVD following plasmin but not hyaluronidase: Implications for combination pharmacologic vitreolysis therapy. Retina 25(1), 38-43 (2005). (Pubitemid 40250406)
79. Hikichi T, Kado M, Yoshida A. Intravitreal injection of hyaluronidase cannot induce posterior vitreous detachment in the rabbit. Retina 20(2), 195-198 (2000). (Pubitemid 30395716)
80. Sumi H, Hamada H, Nakanishi K, Hiratani H. Enhancement of the fibrinolytic activity in plasma by oral administration of nattokinase. Acta Haematol. 84(3), 139-143 (1990). (Pubitemid 20361939)
81. Urano T, Ihara H, Umemura K et al. The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis cleaves and inactivates plasminogen activator inhibitor type 1. J. Biol. Chem. 276(27), 24690-24696 (2001).
82. Takano A, Hirata A, Ogasawara K et al. Posterior vitreous detachment induced by nattokinase (subtilisin NAT): A novel enzyme for pharmacologic vitreolysis. Invest. Ophthalmol. Vis. Sci. 47(5), 2075-2079 (2006). (Pubitemid 46768291)
83. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res. 41(11 Pt 1), 4629-4636 (1981). (Pubitemid 12201384)
84. Uemura A, Nakamura M, Kachi S et al. Effect of plasmin on laminin and fibronectin during plasmin-assisted vitrectomy. Arch. Ophthalmol. 123(2), 209-213 (2005). (Pubitemid 40189708)
85. Li X, Shi X, Fan J. Posterior vitreous detachment with plasmin in the isolated human eye. Graefes Arch. Clin. Exp. Ophthalmol. 240(1), 56-62 (2002). (Pubitemid 36075574)
86. Takano A, Hirata A, Inomata Y et al. Intravitreal plasmin injection activates endogenous matrix metalloproteinase-2 in rabbit and human vitreous. Am. J. Ophthalmol. 140(4), 654-660 (2005). (Pubitemid 41455306)
87. Verstraeten TC, Chapman C, Hartzer M, Winkler BS, Trese MT, Williams GA. Pharmacologic induction of posterior vitreous detachment in the rabbit. Arch. Ophthalmol. 111(6), 849-854 (1993). (Pubitemid 23170602)
88. Hikichi T, Yanagiya N, Kado M, Akiba J, Yoshida A. Posterior vitreous detachment induced by injection of plasmin and sulfur hexafluoride in the rabbit vitreous. Retina 19(1), 55-58 (1999). (Pubitemid 30387541)
89. Gandorfer A, Putz E, Welge-Lüssen U, Grüterich M, Ulbig M, Kampik A. Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy. Br. J. Ophthalmol. 85(1), 6-10 (2001). (Pubitemid 32060187)
90. Gandorfer A, Priglinger S, Schebitz K et al. Vitreoretinal morphology of plasmintreated human eyes. Am. J. Ophthalmol. 133(1), 156-159 (2002). (Pubitemid 34076524)
91. Margherio AR, Margherio RR, Hartzer M, Trese MT, Williams GA, Ferrone PJ. Plasmin enzyme-assisted vitrectomy in traumatic pediatric macular holes. Ophthalmology 105(9), 1617-1620 (1998). (Pubitemid 28513509)
92. Wu WC, Drenser KA, Trese MT, Williams GA, Capone A. Pediatric traumatic macular hole: Results of autologous plasmin enzyme-assisted vitrectomy. Am. J. Ophthalmol. 144(5), 668-672 (2007).
93. Tsukahara Y, Honda S, Imai H et al. Autologous plasmin-assisted vitrectomy for stage 5 retinopathy of prematurity: A preliminary trial. Am. J. Ophthalmol. 144(1), 139-141 (2007). (Pubitemid 46963187)
94. Wu WC, Drenser KA, Lai M, Capone A, Trese MT. Plasmin enzyme-assisted vitrectomy for primary and reoperated eyes with stage 5 retinopathy of prematurity. Retina (Philadelphia, PA) 28(3 Suppl.), S75-S80 (2008). (Pubitemid 351644429)
95. Trese MT, Williams GA, Hartzer MK. A new approach to stage 3 macular holes. Ophthalmology 107(8), 1607-1611 (2000).
96. Sakuma T, Tanaka M, Inoue M, Mizota A, Souri M, Ichinose A. Efficacy of autologous plasmin for idiopathic macular hole surgery. Eur. J. Ophthalmol. 15(6), 787-794 (2005). (Pubitemid 43074708)
97. Azzolini C, D'Angelo A, Maestranzi G et al. Intrasurgical plasmin enzyme in diabetic macular edema. Am. J. Ophthalmol. 138(4), 560-566 (2004). (Pubitemid 39420482)
98. Sakuma T, Tanaka M, Inoue J, Mizota A, Souri M, Ichinose A. Use of autologous plasmin during vitrectomy for diabetic maculopathy. Eur. J. Ophthalmol. 16(1), 138-140 (2006).
99. Hirata A, Takano A, Inomata Y, Yonemura N, Sagara N, Tanihara H. Plasmin-assisted vitrectomy for management of proliferative membrane in proliferative diabetic retinopathy: A pilot study. Retina 27(8), 1074-1078 (2007). (Pubitemid 350304010)
100. Udaondo P, Díaz-Llopis M, García-Delpech S, Salom D, Romero FJ. Intravitreal plasmin without vitrectomy for macular edema secondary to branch retinal vein occlusion. Arch. Ophthalmol. 129(3), 283-287 (2011).
101. Kamei M, Estafanous M, Lewis H. Tissue plasminogen activator in the treatment of vitreoretinal diseases. Semin. Ophthalmol. 15(1), 44-50 (2000). (Pubitemid 30151714)
102. Hesse L, Nebeling B, Schroeder B, Heller G, Kroll P. Induction of posterior vitreous detachment in rabbits by intravitreal injection of tissue plasminogen activator following cryopexy. Exp. Eye Res. 70(1), 31-39 (2000). (Pubitemid 30046872)
103. Hesse L, Chofflet J, Kroll P. Tissue plasminogen activator as a biochemical adjuvant in vitrectomy for proliferative diabetic vitreoretinopathy. Ger. J. Ophthalmol. 4(6), 323-327 (1995).
104. Le Mer Y, Korobelnik JF, Morel C, Ullern M, Berrod JP. TPA-assisted vitrectomy for proliferative diabetic retinopathy: Results of a double-masked, multicenter trial. Retina 19(5), 378-382 (1999). (Pubitemid 30387506)
105. Gandorfer A, Rohleder M, Sethi C et al. Posterior vitreous detachment induced by microplasmin. Invest. Ophthalmol. Vis. Sci. 45(2), 641-647 (2004). (Pubitemid 38140525)
106. Gad Elkareem AM, Willekens B, Vanhove M, Noppen B, Stassen JM, de Smet MD. Characterization of a stabilized form of microplasmin for the induction of posterior vitreous detachment. Curr. Eye Res. 35(10), 909-915 (2010).
107. Sakuma T, Tanaka M, Mizota A, Inoue J, Pakola S. Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes. Invest. Ophthalmol. Vis. Sci. 46(9), 3295-3299 (2005). (Pubitemid 44264318)
108. de Smet MD, Valmaggia C, Zarranz- Ventura J, Willekens B. Microplasmin: Ex vivo characterization of its activity in porcine vitreous. Invest. Ophthalmol. Vis. Sci. 50(2), 814-819 (2009).
109. de Smet MD, Gandorfer A, Stalmans P et al. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: The MIVI I trial. Ophthalmology 116(7), 1349-1355 (2009).
110. Stalmans P, Delaey C, de Smet MD, van Dijkman E, Pakola S. Intravitreal injection of microplasmin for treatment of vitreomacular adhesion: Results of a prospective, randomized, sham-controlled Phase II trial (the MIVI-IIT trial). Retina 30(7), 1122-1127 (2010).
111. Benz MS, Packo KH, Gonzalez V et al. A placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy. Ophthalmology 117(4), 791-797 (2010).
112. Girach A, Kozma-Wiebe P, Pakola S. Ocriplasmin as treatment for symptomatic vitreomacular adhesion: Phase III trial results. Presented at: Knowledge for Growth 2012. Gent, Belgium, 24 May 2012. 113 Zhi-Liang W, Wo-Dong S, Min L, Xiao-Ping B, Jin J. Pharmacologic vitreolysis with plasmin and hyaluronidase in diabetic rats. Retina 29(2), 269-274 (2009).